Neurona Therapeutics secures $102m funding for Phase III trials of NRTX-1001, a stem cell therapy for drug-resistant epilepsy. The therapy aims to reduce seizures and preserve brain function as an alternative to surgery, showing promising results in early trials.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay